Navigation Links
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
Date:1/4/2012

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco.  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.  The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
2. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
3. Telik Announces Second Quarter 2009 Financial Results
4. Telik Reports Preclinical Results at AACR Annual Meeting
5. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
6. Telik Announces New TRAP Drug Discovery Agreement
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
9. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Receipt of Nasdaq Notice
11. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... 2011 ,   ... Matthew Roe as Chief Business Officer. Matthew joins,Crescendo ... Development & Licensing. During a 23-year ... management, acquisition, divestment, and sales,and marketing, and saw ...
... below 100 nanometres have numerous applications ranging from ... participates in a intragated FP7 European Project called ... nanoimprinting techniques (NIL), as a core aspect for ... followed are cost reduction, simpler fabrication process and ...
... classes of fundamental particles. Photons, the quanta of light, ... up atomic nuclei belong to the fermions. Bosons and ... level. This difference is expressed in their quantum statistics. ... was postulated, which was dubbed the anyon. In their ...
Cached Biology Technology:Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2Acrobatics for anyons: New test for elusive fundamental particle proposed 2
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... 2010 American Academy of Ophthalmology (AAO) - Middle ... a report on beta carotene,s ability to ... diseases. The AAO-MEACO meetingthe world,s largest, most comprehensive ... 19 at McCormick Place, Chicago. 9-cis Beta-Carotene ...
... 2010, Singapore A total of 15 world renowned cognitive ... respective fields at the 6th Decade of the Mind Conference ... 2010. Jointly organised by A*STAR,s Institute of High Performance ... NUS,s Temasek Laboratories, it is the first such conference in ...
... University neurobiologists have created mice that can "smell" light, providing ... the neural basis of olfaction. The work, described this ... for the future study of smell and of complex perception ... traditional methods. "It makes intuitive sense to use odors ...
Cached Biology News:Singapore hosts first 'Decade of the Mind' conference in Asia 2Singapore hosts first 'Decade of the Mind' conference in Asia 3Mice that 'smell' light could help us better understand olfaction 2
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... 2-D standards consist of seven reduced, denatured ... carbonic anhydrase, rabbit muscle GAPDH, bovine muscle ... with pIs ranging from 4.5 to 8.5 ... 76,000. These 2-D standards provide calibrated references ...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
Biology Products: